2019-LOW-68745 | |
Researchers at Purdue University have developed two new drugs to treat idiopathic pulmonary fibrosis (IPF). IPF leads to gradual stiffening of the lungs until no gas exchange can occur. There remains an unmet need for treating patients with IPF as current drug candidates including pirfenidone and nintedanib generally exhibit minimal efficacy and may only delay but not prevent disease progression. The new drug candidates created by Purdue researchers target IPF pathologies by delivering therapeutic payloads specifically to two cell types, the infiltrating profibrotic macrophages and the fibrosis-producing myofibroblasts. By targeting the drugs to these two cell types the researchers are able to minimize toxicity to healthy tissues, thereby rendering the drugs much safer than traditional nontargeted therapies. Advantages: -Significant improvement in potency -Can minimize toxicity Potential Applications: -Drug discovery -Treating idiopathic pulmonary fibrosis Technology Validation: Gaining funding for preclinical trials |
|
|
|
Oct 19, 2022
Foreign, Non-PCT
Hong Kong
(None)
(None)
Sep 30, 2022
Foreign, Non-PCT
Hong Kong
(None)
(None)
Jan 21, 2022
NATL-Patent
United States
(None)
(None)
Jul 22, 2020
PCT-Patent
WO
(None)
(None)
Jul 22, 2020
NATL-Patent
Europe
(None)
(None)
Jul 22, 2020
NATL-Patent
China
(None)
(None)
Jul 22, 2020
NATL-Patent
Japan
(None)
(None)
Jul 22, 2020
NATL-Patent
Australia
(None)
(None)
Jul 22, 2020
NATL-Patent
Canada
(None)
(None)
Nov 11, 2019
Provisional-Patent
United States
(None)
(None)
Oct 4, 2019
Provisional-Patent
United States
(None)
(None)
Jul 22, 2019
Provisional-Patent
United States
(None)
(None)
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |